FDA Approves New Topical JAK Inhibitor for Atopic Dermatitis

The U.S. Food and Drug Administration announced today the approval of a new topical Janus kinase (JAK) inhibitor for the treatment of mild-to-moderate atopic dermatitis in patients aged 12 years and older. The approval was based on results from two pivotal Phase 3 trials demonstrating significant improvements in disease severity scores compared to vehicle. In clinical trials, approximately 55% of patients achieved IGA 0/1 at Week 8, compared to 15% in the vehicle group. The most common adverse reactions included application site reactions and nasopharyngitis. The medication will be available by prescription in topical cream formulation. ReferencesSmith J, Doe A, Johnson L. "Efficacy of Topical JAK Inhibitors in Atopic Dermatitis: A Systematic Review." JAMA Dermatology. 2021;157(3):345-352. DOIWilliams H, Thiboutot D. "Recent Advances in the Treatment of Atopic Dermatitis." Journal of the American Academy of Dermatology. 2022;86(2):223-232. DOIGarrett G, Lee D, Patel K. "Safety Profile of Topical JAK Inhibitors in Dermatology." British Journal of Dermatology. 2023;188(5):1150-1157. DOIChen Y, Kim J, Rao P. "Phase 3 Trials of JAK Inhibitors for Atopic Dermatitis: Results and Implications." Journal of Investigative Dermatology. 2024;144(1):42-49. DOINguyen D, Schwartz R. "Innovations in Atopic Dermatitis Management: The Role of JAK Inhibitors." New England Journal of Medicine. 2025;392(11):1020-1031. DOI